Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H20FNO2S |
Molecular Weight | 285.378 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCC(CC1)C2=C(F)C(=CC=C2)S(C)(=O)=O
InChI
InChIKey=UKUPJASJNQDHPH-UHFFFAOYSA-N
InChI=1S/C14H20FNO2S/c1-3-16-9-7-11(8-10-16)12-5-4-6-13(14(12)15)19(2,17)18/h4-6,11H,3,7-10H2,1-2H3
Molecular Formula | C14H20FNO2S |
Molecular Weight | 285.378 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Ordopidine (also known as ACR-325) is a dopaminergic stabilizer that acts as dopamine D2 receptor antagonists with low affinity. Ordopidine under the development of NeuroSearch participated in phase I trials for the treatment of Parkinson's disease and bipolar disorder. Information about the current study of this drug is not available.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01023282
Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:17:48 GMT 2023
by
admin
on
Fri Dec 15 19:17:48 GMT 2023
|
Record UNII |
0P43SIA7J6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034310
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
9388
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545010
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
DTXSID60236146
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
C166429
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
11701939
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
871351-60-9
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
DB05196
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
0P43SIA7J6
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|